SPH3127 Tablets with Dose A
DrugSee Arm description
NCT Number: NCT05770609
To preliminarily evaluate the clinical efficacy of the renin inhibitor SPH3127 Tablets in patients with mild to moderate ulcerative colitis with placebo as a control and determine the recommended dose.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Phase 2
The First Affiliated Hospital,Sun Yat-sen University, Guangzhou, Guangdong, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
See Arm description
See Arm description
See Arm description
Time frame: Week8
Symptom remission rate
Time frame: Week8
Endoscopic remission rate
Time frame: Week8
Clinical remission rate
Time frame: Week2、Week4
Symptom remission rate
Time frame: Approximately 3 months
Incidence of adverse event and serious adverse event
, correlation with study drug
Shanghai Pharmaceuticals Holding Co., Ltd
Industry
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Dose-finding Phase II Clinical Study to Evaluate the Efficacy and Safety of SPH3127 Tablets in the Treatment of Mild to Moderate Ulcerative Colitis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01201122
Colitis, Colitis, Ulcerative
Holon, Israel
View Trial DetailsNCT01033305
Mild to Moderate Ulcerative Colitis
Cork, Co. Cork, Ireland
View Trial DetailsNCT01045018
Colitis, Colitis, Ulcerative
View Trial Details